CN1553793A - Hair follicle neogenesis by injection of follicle progenitor cells - Google Patents
Hair follicle neogenesis by injection of follicle progenitor cells Download PDFInfo
- Publication number
- CN1553793A CN1553793A CNA028042522A CN02804252A CN1553793A CN 1553793 A CN1553793 A CN 1553793A CN A028042522 A CNA028042522 A CN A028042522A CN 02804252 A CN02804252 A CN 02804252A CN 1553793 A CN1553793 A CN 1553793A
- Authority
- CN
- China
- Prior art keywords
- hair follicle
- cell
- skin
- excipient
- progenitor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/10—Hair or skin implants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0627—Hair cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Methods and devices are disclosed for use in the treatment of male pattern baldness and other conditions involving hair loss by facilitating the growth of new hair in the dermis of a living subject. The method involves the steps of atraumatically injecting follicle progenitor cells into the interface between the dermis and the epidermis and allowing the cells to grow into new hair follicles.
Description
The mutual reference of related application
The application requires apply for January 29 calendar year 2001, U.S. Provisional Patent Application serial number No.60/264, No. 806 priority.
The research of subsidizing about federal government or the statement of progress are inapplicable.
Invention field
The present invention relates generally to treat the method for male's zone alopecia and other hair loss disease by the growth that promotes new hair in the skin of living body.More particularly, the present invention relates to the method for the new hair of growth a kind of hair follicle progenitor cells culture in being injected into skin of living body.
Background of invention
Male zone alopecia is a kind of common disease, and it often is to treat by the transplant operation of hair.In this process, get off from the hair follicle in the scalp in non-alopecia zone is cut, thereby and by transplanting the full dream of sending out of realization more all over the face.In fact, in this process,, therefore do not form new hair owing to the limited amount of the hair follicle that can obtain to be used to redistribute.
As everyone knows, the certain kinds cell of finding in the specific substructure in hair follicle has the ability that forms hair follicle complete, normal function of impelling.These cells are called as hair follicle stem cells or are called hair follicle progenitor cells.Referring to following article: R.M.Lavker etc., Journal ofInvestigative Dermatology, 101 (1), Supplement, July 1993,16S-26S; W.C.Weinberg etc., Journal of Investigative Dermatology, 100 (3), March 1993,229-235; J.Kamimura etc., Journal of Investigative Dermatology, 109 (4), October 1997,534-540; Lichti, A.B. etc., Journal of InvestigativeDermatology, 104 (5), Supplement, May 1995,43S-44S; S.H.Yuspa etc., Journal of Investigative Dermatology, 101 (1), Supplement, July 1993,27S-32S; With C.A.B.Jahoda etc., Journal of Investigative Dermatology, 101 (1), Supplement, July 1993,33S-38S.These books have been carried out various experimental works, have set forth all kinds hair follicle stem cells or the CFU-GM function in new hairs external and in various biological skin tissues form by experiment, herein in conjunction with these instructions.
Normally unsuccessful to the trial of using this understanding in the past, for example disclosing in international publication number WO99/01034 will be through the papillose cell cultivated by injection or be transplanted to trial in people's the skin, herein in conjunction with these instructions.Thereby, still need for example in the scalp, form the method for new hair follicle at people's skin, this method does not comprise such as painful process such as skin or hair transplant.
Summary of the invention
On the one hand, the present invention is a kind of method that produces new hair in the skin of living body that comprises epidermis and skin corium.This method comprises and is expelled to hair follicle progenitor cells in the skin and makes this cell grow up to the step of new hair follicle.Preferably, hair follicle progenitor cells is input in the skin with the form of cell cluster.Also preferably CFU-GM bunch is input in the skin, preferably is input to the interface place between corium and the epidermis in AT mode.Found method, always disturbed the survival of institute's transplanted cells and/or normal function and can not cause the growth with hair of inducing of hair follicle usually by the wound transplanted cells of blistering such as surgical sectioning or attraction.
On the other hand, the present invention is a kind of method that produces new hair in skin of living body, and this method comprises the steps: to separate hair follicle progenitor cells, make cell grow, form cell cluster and this cell cluster is expelled in the skin in culture fluid.As above indicated, cell cluster is preferably imported in AT mode, preferably is input to the epidermis/dermal interface place of skin.
On the other hand, the present invention is a kind of method of noinvasive transplanted cells, particularly will be through the hair follicle progenitor cells bunch method that no wound is transplanted of cultivating.The method is to inject a kind of liquid by the interface place between epidermis and corium, epidermis is separated with corium temporarily and produce one and both do not damaged space or the bag that corium does not damage epidermis yet basically, thereby formed the capsule bleb of a protuberance, and in the space of this full of liquid, inject described cell cluster.One skilled in the art will recognize that cell or cell cluster and capsule bleb are implanted into skin when generating.CFU-GM/cell cluster also can be imported into the capsule bleb after the dermis/epidermis interface that forms the capsule bleb.
Method of the present invention makes the hair follicle that derives from patient or other source, for example derives from another person's hair follicle, can generate numerous new hair follicles from one through transplanting each hair follicle of back.More particularly, method of the present invention provides the method for a kind of male's of treatment zone alopecia and other hair loss disease.
On the other hand, the present invention is a kind of device, and this device is a kind of chamber easily with described cell culture to enough maxicells bunch, also is as one described cell cluster to be expelled to instrument in the skin.
By to following research to the detailed description of preferred embodiment that comprises accompanying drawing and appended claim, with obtain other advantage of the present invention and to the concrete feature of the present invention than full appreciation.
Accompanying drawing is described
Fig. 1 is the sectional view of epidermis (1) and corium (2).In view A, inject for example sodium hyaluronate solution by using hypodermic needle and syringe (4), and between epidermis (1) and corium (2), form a capsule bleb (3).In view B, with sharp keen utensil for example dissecting knife (5) pierce through the capsule bleb, be expelled in the capsule bleb by otch (8) and be in the terminal cell cluster (6) of tinsel (7).There is one can help this cell cluster (6) to be deposited on the interior knot (9) of this capsule bleb (3) on this tinsel (7).In view C, this tinsel (7) is partly pulled out from otch (8), and the knot in the tinsel (9) is in the outside of otch (8) like this.Tinsel was selectively kept somewhere in wound several days and as the device that guides epidermis cell to the cell direction growth that is injected into.
It is the microphotograph that 0.0035 inch the terminal structure that crosslinking mixture became by hyaluronic acid and gelatin of 316-stainless steel metal wire (11) forms 14 times of excipient (10) amplifications at diameter that Fig. 2 is one.
Fig. 3 is one, and to be fixed on diameter be that 0.0035 inch the terminal structure of tinsel (11) forms the microphotograph that excipient (12) amplifies 14 times, wherein be planted on this excipient through human dermis's papillose cell of cultivating, and growth is 10 days in culture fluid, to produce agglomerate, this agglomerate is the mixture of the excipient of cell and part degraded.
Fig. 4 is a diagrammatic sketch that is used to inject the cell mass device, and wherein, cell mass/excipient conjugate (12) is fixed on the end of tinsel (11), and is packed in the syringe needle (13) of transdermal syringe.This syringe needle has Intradermal inclined-plane (a 14) weak point, that have sharp especially tip (15).After passing the capsule bleb with this device, when promoting tinsel (11), withdraw from syringe needle (13).Knot (16) on the tinsel (11) can prevent that cell mass from retreating with tinsel, is deposited in the capsule bleb to guarantee cell mass.
Definition
The term " injection " that the present invention uses is defined as any device of use, by break, cut, Break through, puncture or other can open any method on human body skin surface, at intracutaneous or subcutaneous Any process of deposited material. The described skin that breaks can use identical with the step of the described material of deposition Device or different devices finish, can carry out simultaneously, can carry out respectively in the process fast, Perhaps can after the time interval between two steps, carry out.
Term " cell " or " injection cell " or " part cell " that the present invention uses are following any:
One or more of bunches or agglomerate of one or more of cell types, it is adding basically Or do not add structure and form under the excipient (q.v) and form by individual cells is adhered to one another.
Be essentially spherical or miniliform cell cluster or cell mass.
Cell cluster, wherein two or more different types of cells have been organized in each cell cluster Come to provide the structure that is made up of two or more parts, each part is mainly by one type Cellularity.
The term " CFU-GM " that the present invention uses is defined as to have and can transforms into the thin of high specific more Born of the same parents and/or new cell and any kind that peripheral cell is changed into the ability of specific tissue Cell. Because dermal papilla cell can the former place that does not have hair follicle under proper condition Induce the formation of hair follicle, thereby they are considered to CFU-GM.
The term " hair follicle regeneration " that the present invention uses or " hair follicle regeneration " are defined as the generation of hair follicle new, that function is arranged in the former skin that does not have a function hair follicle.
The term " structure formation excipient " that the present invention uses but be defined as the material of any nontoxic, tissue compatible, pharmaceutically acceptable bio-absorbable, but material that should bio-absorbable be essentially liquid before living cells mixes or before joining living cells, and after joining living cells or with become gelatinous, fibrous after living cells mixes or be on-liquid basically.But structure form excipient also refer to before joining living cells be solid, gelatinous, fibrous or be basically on-liquid and liquefaction subsequently or become any material of bio-absorbable.Thereby the function of structure formation excipient is normally wrapped up, is fixed by support, capsule or other mode causes or promote the gathering of cell or growth to make described cell aggregation or cluster so that form cell cluster or cell mass.
Here employed term " capsule bleb " is defined as space, bag, chamber, chamber or the capsule of full of liquid between epiderm skin and corium by injecting that a kind of nontoxic, compatible with health liquid forms.Term " formation of capsule bleb " here is meant basically not and top epidermis and following corium is caused to continue infringement be AT benign, temporary transient situation.
Detailed description of the invention
The present invention includes a kind of method of inducing the growth of new hair follicle, this method is by being expelled to hair follicle progenitor cells in hope grows capsule bleb in the skin of new hair, thereby grows hair normal, that beautification function is arranged.Having this cell of inducing the hair follicle ability can be injected directly in the capsule bleb in the skin, for example form the suspension of excipient composition or use the hypodermic needle injection with the form of preformed cell mass or grumeleuse with cell and structure, this preformed cell mass or grumeleuse or do not contain structure and form excipient or form the excipient be combined into structure, when described cell during at In vitro culture, this structure forms excipient and can dissolve substantially or degrade in a period of time.
In a preferred embodiment, the present invention includes the regenerated method of a kind of hair follicle, it may further comprise the steps:
A) from the biological tissue of hair follicle, provide hair follicle progenitor cells;
B) cultivate this CFU-GM to increase its quantity;
C) make through cultured cells formation cell cluster;
D) there are the epidermis and the dermal interface place of the skin part of or how new hair follicle to form the capsule bleb in hope; And
E) part with cell cluster is expelled in this capsule bleb.
The hair follicle progenitor cells that above-mentioned steps provides in a) preferably obtains from the hair follicle biological tissue of human body.The patient that the hair follicle biological tissue is provided is preferably with that accept injection cell is same people in the step e).Yet, from no matter being that the acquisition hair follicle is possible organ donation people live body or dead or other individualities, because hair follicle progenitor cells has " immune immunity ", and can not be ostracised as heteroplasm usually, so this method will be feasible.When suffering from certain hair loss conditions,,, need to use organ donation people's hair follicle especially if when perhaps patient is indifferent to the color of the quality of duplicating or his or she existing hair if not can be used as the hair follicle of biological tissue in the remaining hair follicle of patient.
The suitable in the method for the invention CFU-GM of using is arranged in the hair follicle structure, for example is positioned at dermal papilla, dermal sheath and bulging district.Can predict, those other cells that are not considered to CFU-GM usually also can be collected from the biological tissue specimen, be cultivated and along with progenitor cell culture is expelled in the human body.For example, comprising epidermal stem cells may induce hair follicle regeneration useful to promoting sooner.Various useful improvement to cultivation CFU-GM method among the present invention is predictable.By using somatomedin, regulating medium, genetically engineered cell and various adjuvants of interpolation and active agent, also can improve the regenerated ability of cell induction hair follicle.
About above-mentioned steps (b), it has been generally acknowledged that hair follicle progenitor cells repeats repeatedly to cultivate the loss that can cause the hair follicle inductive ability.Therefore, the quantity of the cell that can obtain from each independent hair follicle separated structures culture is limited.Yet, for the people of serious alopecia, might obtain, thereby the recovery process that continues hair during the course is up to obtaining required result from the hair follicle biological tissue that uses newborn hair after the method for the present invention.Thereby the CFU-GM that itself is exactly cell in earlier stage can be used in step (b) with (a).In addition, can predict, be used to eliminate the development of the technology of cultured cell hair follicle inducibility restriction, for example, cell repeat use specific growth adjusting medium in going down to posterity.The present invention is predictable to this improvement.
Step (c) has many kinds of modes and finishes.For example, the formation of cell cluster can form by (1) capsule parcel from being essentially the individual cells suspension; (2) in cell, add structure and form excipient; When (3) existing structure to form excipient,, dissolve substantially and substituted by the extracellular matrix that cell produces thereby cause adhered to one another between the cell, structure to form excipient in cultured cell in vitro a period of time.
For step (d), the method for optimizing that forms the capsule bleb before injection cell is: at first with the reversibility key between a stupe weakening epidermis and the corium, then use the syringe needle minimally thorn transdermal of the fine needle of standard specifications, in skin, inject 1% (weight/volume) as hyaluronic acid, sodium salt, phosphate buffered solution.Hyaluronic advantage is that its viscosity has been protected because the fragility of the epidermis lower surface that mechanical trauma caused subsequently, and its high molecular delayed liquid absorption process again.Other high viscosity material such as natural and synthetic Polyethylene Glycol, chondroitin sulfate, dermatan sulfate and other polysaccharide, mucopolysaccharide, protein, glycoprotein, and similar polymer can substitute hyaluronic acid.
For above-mentioned steps (e), the size of the cell mass of injection or the quantity of cell cluster, each bunch and the volume of injecting fluid and composition need be optimized so that obtain best result.The cell part of injecting in this method step (e) can with comprise the liquid combination that structure forms excipient so that this liquid changes into solid in the injection site.This can be used for protecting transplanted most of cell not destroyed by the inflammation after traumatic.Because cell is temporarily surrounded by artificial substratum, so inflammation is limited in the surface of graft.Like this, offside in the cell at center, can not destroyed more by destructive tissue reaction of short time.Structure forms preferably acceptable carrier pharmaceutically of excipient.Preferred its solid can be formed excipient by the structure of bio-absorbable, in a single day so that be injected in the human body, the structure that forms in the injection site can progressively be absorbed in time.
The example that this structure forms excipient is injectable collagen (Zyderm
TM, CollagenAesthetics, Inc.).People's fibrocyte that this product and process are cultivated combines and is expelled in the athymic mice body, successfully induces the spatial graft that fills up that can see.Can survive through the independent subcutaneous injection of cultivating of fibroblast, and be the first-selected cell of generally acknowledging, but when it does not combine with collagen vehicle, can the necrosis of generative center nodal-like.Collagen stroma can provide a kind of stroma that is of value to cell function and survives in vivo.
Remmler D, Thomas JR, Mazoujian G, Pentland A, Schechtman K, Favors S, and Bauer E " Use of Injectable Cultured Human Fibroblasts forPercutaneous Tissue Implantation.An experimental study, Arch OtolaryngolHead Neck Surg 1989 Jul; 115:837-44 " article in announced these results, instruct in conjunction with these at this.
Other structure forms excipient and comprises Pluronic
TMSurfactant, it is that this polymer has the critical solution temperature consistent with body temperature by the water-soluble polymer of poly-(ethylene oxide-propylene oxide).Thereby cell mass can be suspended in the cold Pluronic solution, injected then.Then, the liquid of injection is become hydrogel by intensification, thereby cell mass is stabilized in the substrate to help cell mass to survive in initial transplanting wound.
Other temperature reversible hydrogel is known, for example the hydrogel that is become based on N-dimethyl N-isopropylacrylamide.These polymer can be by bio-absorbable through chemical modifications, and has suitable degradation rate.
The structure that can form structure after other is injected in vivo in position forms excipient, comprises the liquid system that various two parts are crosslinked.In this case, injection device need be connected to two syringes on the two-tube hypodermic needle.Cell mass will be suspended in a kind of component, the A part (for example, but a kind of component that contains the polymer of crosslinkable bio-absorbable), and another kind of component, B partly contain cross-linking agent.But polymer and cross-linking agent can be selected from various materials with bio-capacitivity and bio-absorbable.For example, A part can be a Fibrinogen and the B part can be a thrombin.Another is human serum albumin and poly-(ethylene glycol)-double amber imide acyl group succinic acid to useful in an embodiment of the present invention composition.
Be to form at cultured cell in vitro to specify the early stage of size and shape cell mass another opportunity of selecting utilization structure to form excipient.In this case, need a kind of solid, porous excipient to think that cell adhesion provides high surface area.Along with growth, breeding and the cell of cell by adhering to mutually that the n cell epimatrix produces, the excipient that plays the framework effect substitutes by bio-absorbable and by the extracellular matrix material basically.
For above-mentioned reasons, any excipient that uses in the method for the invention is preferably selected from: but the polymer of the bio-absorbable of collagen, hot inversion hydrogel, chemical crosslinking, in-situ cross-linked hydrogel, Fibrinogen, thrombin, dextrin, amylose, hyaluronic acid, gelatin, chondroitin sulfate, dermatan sulfate, polysaccharide, mucopolysaccharide, protein, glycoprotein and above-mentioned any derivant, copolymer or other variant.
The method that further selection with the cell materials implanted of injecting is related to and controls angle between hair shaft outlet and the skin.As everyone knows, the angle of the hair of scalp zones of different changes, and the concordance of these angles and regulatable variation are very important to the full beauty treatment outward appearance of sending out all over the face.Therefore, the present invention can predict in the improvement of the cell transplantation method of its direction that grows from skin of regulation and control and angle the New Development dry stool that grows because of hair follicle regeneration.
Set forth a kind of like this method among the embodiment 2, be about to the rustless steel fine wire and in skin, kept somewhere several days, epidermis is grown downwards.This growth has not only guaranteed to interact between the hair follicle progenitor cells of epidermis cell and transplanting, and provide lead to skin surface, as the passage of the guide of the direction of growth of hair follicle and the regulation and control of dry angle.Also can predict, owing to do not need to remove, other is as being had special effect by the residual fiber that the polymer of bio-absorbable constitutes by synthetic or natural.
Further set forth the present invention in the example below, but these examples can not be construed to limit the scope of the present invention.
Embodiment 1: the preparation of injection device
The long biological tissue skin boring that has the The scalp with hair place to carry out 4 mm dias, consistency of thickness behind the alopecia patient brain of male zone.Follicle bulb is scaled off from hair follicle, and dermal papilla is split.According to A.G Messenger, British Journal of Dermatology, 110, the method that 685-689 (1984) describes in culture fluid with dermal papilla cell (DP cell) amplification, being taught in this and combining reference of this piece article.
Device of the present invention has illustrated that in Fig. 4 its preparation process is as follows: 100 milligrams of hyaluronate sodiums and 100 milligrams of pigskin gelatins are dissolved in makes 100 ml solns (HA-gelatin solution) in the distilled water.With low-molecular-weight poly-(d, 1-lactide-50% Acetic acid, hydroxy-, bimol. cyclic ester) (PLGA) granule grinding, the screening size is mixed formation thick paste thing at the granule of 100-200 micrometer range with the HA-gelatin solution.With one 30 degrees centigrade, to comprise diameter be that 0.0035 inch the nodular stainless steel metal wire of long filament is filled in the tip of 18 bore hypodermic needles with pastel, and makes its bone dry.
The PLGA granule is dissolved in the dichloromethane, remaining HA-gelatin excipient is by crosslinked in 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide (EDC) solution that is immersed in 0.1% (weight/volume), and EDC is dissolved in acetone and water is respectively in the mixed liquor of 90: 10 (weight/volume).Then, this installs with the acetone rinsing and is immersed in 70% isopropyl acetone/aqueous solution and sterilizes the reuse rinsed with sterile water.To scrape from culture dish through the DP cell of the fused layer cultivated with the HA-gelatin excipient that exposes on the syringe needle, join in this device.Then, the syringe needle of repopulating cell places a flask culture base, makes the cell growth that will shift and breeds an about week, adhere to mutually between the cell during this period, and the HA-gelatin excipient is fully degraded and dissolved.
Embodiment 2: the injection of cultured cell
The scalp of one fritter baldness is at first softening with warm water, and uses Emia
TMLidocaine emulsifiable paste (Astra Pharmaceutical Products, Inc., Westborough, MA 01581) anesthesia, cover Tegaderm
TMAbout 30 minutes of dressing (MN 55144 for 3M, St.Paul).Then, scalp is wiped clean, then swabbed 70% isopropyl alcohol.After at first skin being warmed, with sodium hyaluronate solution (Healon with stupe
TM, Pharmacia-Upjohn, Kalamazoo, MI 49001) and be expelled to the place of wishing natural on-off cycles of hair growth.Then, be used in the capsule bleb of the punctures formation that contains the DP cell mass among the embodiment 1 as described above.When withdrawing from syringe needle, hold fine wire and guarantee that the cell mass that injects does not withdraw from syringe needle.Remove tinsel then until the outside of this knot in puncture wound.Remove tinsel, thereby finish whole process, perhaps selectively, tinsel Tegaderm
TMDressing is cemented in and is retained on the skin in the wound, after about 5 days tinsel is removed so that the epidermal growth towards the cell that is moved into to be provided.On scalp, can produce a plurality of capsule blebs, thereby the multiple injection cell obtains the new hair of desired density in each capsule bleb.
In about 8 weeks after the injection, the regeneration of hair follicle has just been finished, and the patient can begin to experience the growth of hair new, organizational project, and the hair of this growth is normal and the same with the hair of donor site fully.
Though now the present invention is described, and gives an example with some specific embodiments, those skilled in the art is according to the described various changes that will draw in comprising variation, add and being omitted in.Therefore, these changes also will be contained by the present invention, and scope of the present invention only can be done the most generalized explanation according to appended claim in accordance with the law and defines.
Claims (20)
1. method that in human body skin, forms new hair follicle, described skin comprises skin corium and epidermal area, said method comprising the steps of:
To have wound ground through the part of the hair follicle progenitor cells of cultivating bunch and inject by the skin corium of described human body skin and the vesicle of epidermal area definition, and
Make the cell growth to form new hair follicle.
2. method that forms new hair follicle in human body comprises:
A) provide the hair follicle progenitor cells that from the biological tissue of hair follicle, derives;
B) by being accelerated, it cultivates described CFU-GM;
C) make through cultured cells formation cell cluster;
D) there are the epidermis and the dermal interface place of the skin part of or how new hair follicle to form the capsule bleb in hope;
E) part with described cell cluster is expelled in the described capsule bleb; And
F) make described cell growth to form new hair follicle.
3. method as claimed in claim 2, wherein the CFU-GM that provides in the step a) obtains in the injected human body from step (e).
4. method as claimed in claim 2 is wherein injected the cell that the interior hair follicle progenitor cells culture of human body skin also comprises at least a other type.
5. method as claimed in claim 4, the cell of wherein said other type obtains from epidermis.
6. forming excipient with at least a structure before method as claimed in claim 2, wherein said hair follicle progenitor cells culture are injected in the human body skin combines.
7. method as claimed in claim 6, but wherein said structure forms polymer that excipient is selected from the bio-absorbable of collagen, hot inversion hydrogel, chemical crosslinking, in-situ cross-linked hydrogel, Fibrinogen, thrombin, dextrin, amylose, hyaluronic acid, gelatin, chondroitin sulfate, dermatan sulfate, polysaccharide, mucopolysaccharide, protein, glycoprotein and above-mentioned any derivant, copolymer or other variant, and other pharmaceutically acceptable excipient.
8. method as claimed in claim 6, it is the crosslinking mixture of hyaluronic acid and gelatin that wherein said structure forms excipient.
9. method as claimed in claim 2, wherein said capsule bleb is by forming at a kind of viscosity solution of subcutaneous injection, and the solute for preparing described viscosity solution is selected from: natural and synthetic hyaluronic acid, Polyethylene Glycol, chondroitin sulfate, dermatan sulfate, and other polysaccharide, mucopolysaccharide, protein, glycoprotein and similar polymer.
10. method as claimed in claim 2, wherein said capsule bleb is by forming at the subcutaneous injection sodium hyaluronate solution.
11. method as claimed in claim 2, wherein the no wound of injecting step (e) is finished.
12. a device of injecting through the hair follicle progenitor cells of cultivating comprises hypodermic syringe needle, is contained in described needle tip intracavity through hair follicle progenitor cells bolt of cultivating and the device of discharging described cell bolt after described syringe needle injects skin.
13. device as claimed in claim 11, wherein said is the mixture that cell and structure form excipient through the hair follicle progenitor cells bolt of cultivating.
14. device as claimed in claim 12, wherein said cell are through the dermal papilla cell of cultivating, it is the crosslinking mixture of hyaluronic acid and gelatin that described structure forms excipient.
15. one kind forms the method for new hair follicle at human body, comprising:
A) provide the hair follicle progenitor cells that from the biological tissue of hair follicle, derives;
B) by being accelerated, it cultivates described CFU-GM;
C) make through cultured cells formation cell cluster;
D) making described cell cluster and structure form excipient combines;
E) there are the epidermis and the dermal interface place of the skin part of or how new hair follicle to form the capsule bleb in hope;
F) part with cell cluster is expelled in the described capsule bleb; And
G) make described cell growth to form new hair follicle.
16. method as claimed in claim 15, the described CFU-GM that wherein provides in the step a) obtain in the injected human body from step (f).
17. method as claimed in claim 15 is wherein injected the cell that the interior hair follicle progenitor cells culture of human body skin also comprises at least a other type.
18. method as claimed in claim 17, the cell of wherein said other type obtains from epidermis.
19. method as claimed in claim 15, wherein said structure forms the crosslinking mixture that excipient comprises hyaluronic acid and gelatin.
20. as the method for claim 15, wherein step e) and f) carry out simultaneously.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26480601P | 2001-01-29 | 2001-01-29 | |
| US60/264,806 | 2001-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1553793A true CN1553793A (en) | 2004-12-08 |
Family
ID=23007681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA028042522A Pending CN1553793A (en) | 2001-01-29 | 2002-01-29 | Hair follicle neogenesis by injection of follicle progenitor cells |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1367982A2 (en) |
| JP (1) | JP2004517934A (en) |
| KR (1) | KR20030082576A (en) |
| CN (1) | CN1553793A (en) |
| BR (1) | BR0206796A (en) |
| CA (1) | CA2435709A1 (en) |
| MX (1) | MXPA03006714A (en) |
| WO (1) | WO2002060396A2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109908179A (en) * | 2019-03-08 | 2019-06-21 | 广西医科大学第一附属医院 | A kind of injection medicament of hair follicle progenitor cells |
| CN111840330A (en) * | 2020-08-03 | 2020-10-30 | 北京诺赛启研再生医学研究院有限公司 | Anti-hair loss repairing composition and application |
| CN112153957B (en) * | 2018-04-13 | 2023-12-26 | 北卡罗来纳州立大学 | Use of microneedle patch for promoting hair growth |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030161815A1 (en) | 2002-02-12 | 2003-08-28 | Intercytex Limited | Cell delivery system |
| US20030198646A1 (en) * | 2002-04-17 | 2003-10-23 | Stenn Kurt Stricker | Compositions and methods for inducing new hair follicle formation and hair growth in a desired orientation |
| US7785876B2 (en) | 2002-11-14 | 2010-08-31 | Aderans Research Institute, Inc. | Cultivation of hair inductive cells |
| EP1660172A1 (en) * | 2003-08-26 | 2006-05-31 | Alza Corporation | Device and method for intradermal cell implantation |
| US7597885B2 (en) * | 2004-03-26 | 2009-10-06 | Aderans Research Institute, Inc. | Tissue engineered biomimetic hair follicle graft |
| AU2012204059B2 (en) * | 2005-03-29 | 2015-01-15 | The Trustees Of The University Of Pennsylvania | Methods for generating new hair follicles, treating baldness and hair removal |
| AU2006230187B2 (en) | 2005-03-29 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Methods for generating new hair follicles, treating baldness, and hair removal |
| JP5263756B2 (en) | 2005-09-30 | 2013-08-14 | 国立大学法人 岡山大学 | Cell culture method and cell culture |
| EP1945757B1 (en) * | 2005-10-17 | 2017-12-06 | Aderans Research Institute, Inc. | Method of delivering hair follicle progenitor cells to the skin |
| US20070148138A1 (en) | 2005-11-22 | 2007-06-28 | Aderans Research Institute, Inc. | Hair follicle graft from tissue engineered skin |
| EP1986731A4 (en) | 2006-02-09 | 2012-11-07 | Aderans Res Inst Inc | Apparatus and methods for delivering fluid and material to a subject |
| GB0605450D0 (en) | 2006-03-17 | 2006-04-26 | Intercytex Ltd | Cell co-culture |
| BRPI0719509A2 (en) | 2006-09-28 | 2013-12-31 | Follica Inc | METHODS, KITS AND COMPOSITIONS FOR GENERATING NEW HAIR FOLICULES AND HAIR GROWTH |
| JP2014500275A (en) | 2010-12-06 | 2014-01-09 | フォリカ，インコーポレイテッド | Methods for treating baldness and for promoting hair growth |
| EP2937098A1 (en) * | 2014-04-24 | 2015-10-28 | Clinica Dermatologica Ercilla | A pharmaceutical composition comprising a suspension of total cells obtained from hair follicle and plasma derived growth factors for promoting hair follicle regeneration |
| JP2020130771A (en) * | 2019-02-22 | 2020-08-31 | キヤノン株式会社 | Processing device, processing method and program |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8604360D0 (en) * | 1986-02-21 | 1986-03-26 | Univ Dundee | Stimulation of hair growth |
| AU8282998A (en) * | 1997-07-01 | 1999-01-25 | Jerry E. Cooley | Method for producing new hair growth |
| DE10005329A1 (en) * | 2000-02-08 | 2001-09-20 | Albert Scheller | Stimulating growth of hair, e.g. on the head, eyebrows or eyelashes, by subcutaneous application of a preparation containing stem cells and/or preformed hair cells |
-
2002
- 2002-01-29 EP EP02703283A patent/EP1367982A2/en not_active Withdrawn
- 2002-01-29 BR BR0206796-0A patent/BR0206796A/en not_active IP Right Cessation
- 2002-01-29 JP JP2002560590A patent/JP2004517934A/en not_active Abandoned
- 2002-01-29 MX MXPA03006714A patent/MXPA03006714A/en unknown
- 2002-01-29 CN CNA028042522A patent/CN1553793A/en active Pending
- 2002-01-29 WO PCT/US2002/002643 patent/WO2002060396A2/en not_active Application Discontinuation
- 2002-01-29 KR KR10-2003-7009943A patent/KR20030082576A/en not_active Application Discontinuation
- 2002-01-29 CA CA002435709A patent/CA2435709A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112153957B (en) * | 2018-04-13 | 2023-12-26 | 北卡罗来纳州立大学 | Use of microneedle patch for promoting hair growth |
| CN109908179A (en) * | 2019-03-08 | 2019-06-21 | 广西医科大学第一附属医院 | A kind of injection medicament of hair follicle progenitor cells |
| CN111840330A (en) * | 2020-08-03 | 2020-10-30 | 北京诺赛启研再生医学研究院有限公司 | Anti-hair loss repairing composition and application |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002060396A3 (en) | 2003-03-13 |
| JP2004517934A (en) | 2004-06-17 |
| KR20030082576A (en) | 2003-10-22 |
| WO2002060396A2 (en) | 2002-08-08 |
| CA2435709A1 (en) | 2002-08-08 |
| EP1367982A2 (en) | 2003-12-10 |
| BR0206796A (en) | 2004-02-03 |
| MXPA03006714A (en) | 2005-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1553793A (en) | Hair follicle neogenesis by injection of follicle progenitor cells | |
| AU2018201536B2 (en) | Skin Substitutes And Methods For Hair Follicle Neogenesis | |
| US6991652B2 (en) | Tissue engineering composite | |
| KR101236363B1 (en) | Particles for soft tissue augmentation | |
| US6911202B2 (en) | Cosmetic repair using cartilage producing cells and medical implants coated therewith | |
| US6884427B1 (en) | Filamentary means for introducing agents into tissue of a living host | |
| US9023380B2 (en) | Hair follicle graft from tissue engineered skin | |
| TW200803877A (en) | Hair grafts derived from plucked hair | |
| US20030161815A1 (en) | Cell delivery system | |
| CN1424916A (en) | Implantable substrates for healing connective tissue | |
| CN1735685A (en) | Treatment of tissue with undifferentiated mesenchymal cells | |
| US20040068284A1 (en) | Method for stimulating hair growth and kit for carrying out said method | |
| CN107164310A (en) | Method for reconstructing hair follicle in vivo | |
| CN101062429A (en) | Method for constructing tissue engineering double-layered skin and the application thereof | |
| AU771161B2 (en) | Filamentary means for introducing agents into tissue of a living host | |
| US20030198646A1 (en) | Compositions and methods for inducing new hair follicle formation and hair growth in a desired orientation | |
| CN107250348A (en) | Developed using expression LGR4, LGR5 and LGR6 epithelial stem cell in organizations and using the method for the micro- aggregation body unit of least polar functioning cell | |
| US20110244006A1 (en) | Microsphere skin treatment | |
| KR101198196B1 (en) | Cell Engraftment Yarn for Promoting Engraftment of Cells | |
| RU2277423C1 (en) | Method for repairing structural and functional changes in connective tissue | |
| AU2002236914A1 (en) | Hair follicle neogenesis by injection of follicle progenitor cells | |
| CN1071568A (en) | The skin equivalent of compound work | |
| RU2195940C2 (en) | Method for regeneration of an articular cartilage | |
| CN116392646A (en) | Barrier membrane for guiding bone regeneration | |
| JP2004254759A (en) | Composite material for promoting hair growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |